201 related articles for article (PubMed ID: 34775535)
21. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
[TBL] [Abstract][Full Text] [Related]
22. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
Slimano F; Netzer F; Borget I; Lemare F; Besse B
Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
[TBL] [Abstract][Full Text] [Related]
24. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
[TBL] [Abstract][Full Text] [Related]
25. Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.
Yokoyama S; Tamaru S; Tamaki S; Nakanishi D; Mori A; Yamakawa T; Ao T; Sakata Y; Mizuno T; Iwamoto T; Watanabe K; Simomura M; Kawakami K; Konishi N; Kageyama S; Ohtani S; Yamada T; Ban S; Ooi K
Clin Breast Cancer; 2018 Apr; 18(2):e157-e165. PubMed ID: 28735677
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
[TBL] [Abstract][Full Text] [Related]
27. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
[TBL] [Abstract][Full Text] [Related]
28. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
Celio L; Bonizzoni E; Bajetta E; Sebastiani S; Perrone T; Aapro MS
Support Care Cancer; 2013 Feb; 21(2):565-73. PubMed ID: 22869054
[TBL] [Abstract][Full Text] [Related]
29. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
30. Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.
Meattini I; Francolini G; Scotti V; De Luca Cardillo C; Cappelli S; Meacci F; Furfaro IF; Muntoni C; Scoccianti S; Detti B; Mangoni M; Nori J; Orzalesi L; Fambrini M; Bianchi S; Livi L
Med Oncol; 2015 Mar; 32(3):80. PubMed ID: 25698536
[TBL] [Abstract][Full Text] [Related]
31. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
[TBL] [Abstract][Full Text] [Related]
32. Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making.
Hutton B; Clemons M; Mazzarello S; Kuchuk I; Skidmore B; Ng T
Cancer Treat Rev; 2015 Dec; 41(10):951-9. PubMed ID: 26442474
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
[TBL] [Abstract][Full Text] [Related]
34. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide.
Hesketh PJ; Younger J; Sanz-Altamira P; Hayden M; Bushey J; Trainor B; Krentzin M; Nowd P; Arnaoutakis K; Hesketh AM
Support Care Cancer; 2009 Aug; 17(8):1065-70. PubMed ID: 19066985
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
36. Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.
Inui N
Med Oncol; 2017 May; 34(5):77. PubMed ID: 28365889
[TBL] [Abstract][Full Text] [Related]
37. Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy: A Retrospective Observational Study.
Kawazoe H; Murakami A; Yamashita M; Nishiyama K; Kobayashi-Taguchi K; Komatsu S; Aoki R; Kusakabe E; Yamasawa H; Yakushijin Y; Nakamura T; Kamei Y
Clin Ther; 2018 Dec; 40(12):2170-2179. PubMed ID: 30392814
[TBL] [Abstract][Full Text] [Related]
38. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.
Tan L; Liu J; Liu X; Chen J; Yan Z; Yang H; Zhang D
J Exp Clin Cancer Res; 2009 Sep; 28(1):131. PubMed ID: 19775450
[TBL] [Abstract][Full Text] [Related]
39. Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials.
Yeo W; Mo FKF; Yip CCH; Yeo VA; Li L; Lau TKH; Lai KT; Chan VTC; Wong KH; Pang E; Cheung M; Chan V; Kwok CCH; Suen JJS; Molassiotis A
Oncologist; 2021 Dec; 26(12):e2288-e2296. PubMed ID: 34516038
[TBL] [Abstract][Full Text] [Related]
40. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]